J R Corvalán
About
In The Last Decade
J R Corvalán
17 papers receiving 709 citations
Peers
Comparison fields: 5 of 74
- Radiology, Nuclear Medicine and Imaging 427
- Molecular Biology 342
- Oncology 334
- Immunology 227
- Pulmonary and Respiratory Medicine 110
Countries citing papers authored by J R Corvalán
This map shows the geographic impact of J R Corvalán's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J R Corvalán with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J R Corvalán more than expected).
Fields of papers citing papers by J R Corvalán
This network shows the impact of papers produced by J R Corvalán. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J R Corvalán. The network helps show where J R Corvalán may publish in the future.
Co-authorship network of co-authors of J R Corvalán
This figure shows the co-authorship network connecting the top 25 collaborators of J R Corvalán. A scholar is included among the top collaborators of J R Corvalán based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J R Corvalán. J R Corvalán is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. | 288 |
| 2 | 4 | |
| 3 | 3 | |
| 4 | 7 | |
| 5 | 23 | |
| 6 | Development of a dual label fluorescence technique that can be utilized to elucidate the mechanism of action of monoclonal antibody-drug conjugates. | 7 |
| 7 | 30 | |
| 8 | 30 | |
| 9 | 26 | |
| 10 | 60 | |
| 11 | T helper cells required for the in vitro primary antibody response to SRBC are neither SRBC-specific nor MHC-restricted. | 2 |
| 12 | Defective monocyte accessory function due to surface sulphydryl (SH) oxidation in rheumatoid arthritis. | 29 |
| 13 | 31 | |
| 14 | 181 | |
| 15 | T-cell hybrids as a source of antigen-specific factors. | 3 |
| 16 | 56 | |
| 17 | 9 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.